ArticleMolecular and cellular biochemistry2017
Hyperoside inhibits the effects induced by oxidized low-density lipoprotein in vascular smooth muscle cells via oxLDL-LOX-1-ERK pathway.
Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Systematic review of Chinese medicine for the treatment of atherosclerosis.Frontiers in cardiovascular medicine · 2025Pooled it
- Review
- Hyperoside Nanomicelles Alleviate Atherosclerosis by Modulating the Lipid Profile and Intestinal Flora Structure in High-Fat-Diet-Fed Apolipoprotein-E-Deficient Mice.Molecules (Basel, Switzerland) · 2023Article
- Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review.Journal of inflammation research · 2023Review
- Identification of Q-Markers from Hedan Tablet by employing "spider-web" mode and taking compounds' hepatotoxicity into account.Chinese herbal medicines · 2022Article
- Anti-atherosclerotic effects of genistein in preventing ox-low-density lipoprotein-induced smooth muscle-derived foam cell formation via inhibitingAnnals of translational medicine · 2022Article
- Natural Flavonoids Derived From Fruits Are Potential Agents Against Atherosclerosis.Frontiers in nutrition · 2022Review
- Article
- Anti-Inflammatory Effects of Thymoquinone in Atherosclerosis: A Mini Review.Frontiers in pharmacology · 2021Review
- A Novel Herbal Medicine for Dyslipidemia: Assessments in Experimental Models.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis.Current atherosclerosis reports · 2019Review
- Electronegative LDL from Rabbits Fed with Atherogenic Diet Is Highly Proinflammatory.Mediators of inflammation · 2019Article
- The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Hyperoside is a major active constituent in many medicinal plants traditionally used in Chinese medicines for their anti-inflammatory, antioxidative, and vascular protective effects. Recent studies have focused on the protective effects of hyperoside on hyperlipidemia. However, the molecular mechanisms underlying these effects are unknown. In this study, vascular smooth muscle cells (VSMCs) were treated in vitro with oxidized low-density lipoprotein (oxLDL) in the presence or absence of hyperoside. Western blotting, quantitative PCR, and tetrazolium assay were used to detect lectin-like oxLDL receptor-1 (LOX-1) expression and extracellular signal-regulated kinases (ERK) activation, and to determine VSMCs viability. The results demonstrated that oxLDL promoted LOX-1 expression, ERK activation, and proliferation in VSMCs. Hyperoside significantly inhibited the oxLDL-stimulated effects after long time exposure. However, it promoted ERK activation directly following a short incubation duration (25 min). In conclusion, hyperoside inhibits oxLDL-induced LOX-1 expression, ERK activation, and cell proliferation through the oxLDL-LOX-1-ERK pathway in VSMCs. Our findings suggest a novel role of hyperoside in treating and preventing atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.